Patent intelligence · US
US 10501551
Multivalent and multispecific 41BB-binding fusion proteins
Multivalent and multispecific 41BB-binding fusion proteins
Patent details — US 10501551
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 10, 2019
- Expiration
- Dec 5, 2039
- Applicant
- Inhibrx, Inc.
- Claims
- 64
- CPC classes
- A61P, A61P29/00, A61P35/00, A61P37/04
Quick answer
US 10501551 (Multivalent and multispecific 41BB-binding fusion proteins) is held by Inhibrx, Inc.. Status: granted. Granted Dec 10, 2019. Expires Dec 5, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Inhibrx, Inc.
- Grant date
- Expiration
- Claims
- 64
- CPC classes
- A61P, A61P29/00, A61P35/00, A61P37/04, A61P43/00
More from Inhibrx, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12365728
DLL3 single domain antibodies and therapeutic compositions thereof
granted -
US 12331132
Multispecific polypeptide constructs having constrained CD3 binding and related methods and uses
granted -
US 12331126
OX40-binding polypeptides and uses thereof
granted -
US 12227584
Multivalent and multispecific OX40-binding fusion proteins
granted -
US 12187804
Multivalent and multispecific 41BB-binding proteins
granted -
US 12084502
CD33-binding polypeptides and uses thereof
granted -
US 12043667
CLEC12a binding polypeptides and uses thereof
granted -
US 12012459
OX40-binding polypeptides and uses thereof
granted
Frequently asked questions
What is US patent 10501551?
US 10501551 (Multivalent and multispecific 41BB-binding fusion proteins) is held by Inhibrx, Inc.. Status: granted. Granted Dec 10, 2019. Expires Dec 5, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10501551?
Inhibrx, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 35 pharmaceutical patents for this assignee.
When does US 10501551 expire?
Our index shows an expiration date of Dec 5, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.